Trial Profile
An open-label study in healthy subjects and in subjects with stable impaired hepatic function to assess the effect of moderate hepatic impairment on licarbazepine pharmacokinetics and metabolism after a single dose of 1000 mg licarbazepine IR [immediate release] tablets
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Licarbazepine (Primary)
- Indications Bipolar disorders
- Focus Pharmacokinetics
- Sponsors Novartis
- 14 Feb 2007 New trial record.